Dupilumab, used to treat atopic dermatitis, has been linked to an increased risk of various conditions, including psoriasis, autoimmune skin diseases, and ocular surface diseases. There are also reports of an association between dupilumab use and a higher risk of lymphoma, including cutaneous t-cell lymphoma. The specific risks and benefits of dupilumab use are not entirely clear, with some reports suggesting increased risks of certain conditions, while others note associations with lower mortality in certain patient groups.